Nipro Competitors and Similar CompaniesClear all
Nipro's competitors and similar companies include West Pharmaceutical Services, Eisai, Kuraray, Takeda, Astellas Pharma and Nikkiso.
 Nipro Nipro Corporation (ニプロ株式会社) is a company that has expertise in medical devices, pharmaceuticals, pharma packaging, and regenerative medicine business. |  West Pharmaceutical Services West Pharmaceutical Services is a company that designs and manufactures integrated containment and delivery systems. |  Eisai Eisai is a research-based human health care company that discovers, develops, packages, and markets pharmaceutical products. |  Kuraray Kuraray (株式会社クラレ) is a company that manufactures chemicals, synthetic and chemical fibers, and other materials. |  Takeda Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Nikkiso Nikkiso (日機装株式会社) is a company that engages in industrial, precision equipment, aerospace, and medical businesses. | |
Founding Date | Founding Date 1954 | Founding Date 1923 | Founding Date 1941 | Founding Date 1926 | Founding Date 1781 | Founding Date 1923 | Founding Date 1953 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations West Whiteland Township, US HQ Munro, AR Macquarie Park, AU São Paulo, BR Shanghai, CN Shanghai, CN Tibito, CO see more | Locations Chiyoda, JP HQ Victoria, AU Beveren, BE Seneffe, BE Zwijndrecht, BE São Paulo, BR Shanghai, CN see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | ||||
Employees | Employees 38,117 | Employees 10,6001% decrease | Employees 11,067 | Employees 11,906 | Employees 49,281 | Employees 14,754 | Employees 8,131 |
Valuation ($) | Valuation ($) 1.5 b | Valuation ($) 23.1 b | Valuation ($) 9.6 b | Valuation ($) 4.4 b | Valuation ($) 43.7 b | Valuation ($) 20.8 b | Valuation ($) 440.7 m |
Financial | |||||||
Revenue (est.) | Revenue (est.) ¥586.8b (FY, 2024) | Revenue (est.) $2.9b (FY, 2023) | Revenue (est.) ¥741.8b (FY, 2024) | Revenue (est.) ¥780.9b (FY, 2023) | Revenue (est.) ¥4.3t (FY, 2024) | Revenue (est.) ¥1.6t (FY, 2024) | Revenue (est.) ¥192.6b (FY, 2023) |
Cost of goods | Cost of goods ¥356.6b (FY, 2024) | Cost of goods $1.8b (FY, 2023) | Cost of goods ¥115.4b (FY, 2024) | Cost of goods ¥463.8b (FY, 2023) | Cost of goods ¥698.7b (FY, 2024) | Cost of goods ¥134.6b (FY, 2024) | Cost of goods ¥135.3b (FY, 2023) |
Gross profit | Gross profit ¥230.2b (FY, 2024) | Gross profit $1.1b (FY, 2023) | Gross profit ¥638.4b (FY, 2024) | Gross profit ¥317.1b (FY, 2023) | Gross profit ¥3.6t (FY, 2024) | Gross profit ¥1.5t (FY, 2024) | Gross profit ¥58b (FY, 2023) |
Net income | Net income ¥12.2b (FY, 2024) | Net income $593.4m (FY, 2023) | Net income ¥43.8b (FY, 2024) | Net income ¥42.3b (FY, 2023) | Net income ¥144.2b (FY, 2024) | Net income ¥17b (FY, 2024) | Net income ¥9.1b (FY, 2023) |
Operating ⚠ | |||||||
Filed Trials Products (Oncology) | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) 2 (Jul, 2018) | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) 5 (May, 2021) | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 11 (Jul, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) N/A |
Phase I/II Trials Products (Oncology) | Phase I/II Trials Products (Oncology) N/A | Phase I/II Trials Products (Oncology) N/A | Phase I/II Trials Products (Oncology) 6 (Jul, 2019) | Phase I/II Trials Products (Oncology) N/A | Phase I/II Trials Products (Oncology) 13 (Jul, 2023) | Phase I/II Trials Products (Oncology) N/A | Phase I/II Trials Products (Oncology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 9 (Jul, 2019) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 10 (Jul, 2019) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 6 (Jul, 2023) | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) N/A |
For sources of this data, please see the company profile
View Company Profiles
West Pharmaceutical Services
HQ
West Whiteland Township, US
Employees
10,600↓ 1% decrease
West Pharmaceutical Services is a company that designs and manufactures integrated containment and delivery systems.
View companyEisai
HQ
Bunkyo City, JP
Employees
11,067
Eisai is a research-based human health care company that discovers, develops, packages, and markets pharmaceutical products.
View companyKuraray
HQ
Chiyoda, JP
Employees
11,906
Kuraray (株式会社クラレ) is a company that manufactures chemicals, synthetic and chemical fibers, and other materials.
View companyTakeda
HQ
Tokyo, JP
Employees
49,281
Takeda Pharmaceutical is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company